EC Number   |
Protein Variants |
Reference |
|---|
   3.1.4.41 | D259G |
site-directed mutagenesis, the mutant shows highly reduced sphingomyelinase and hemolytic activity compared to the wild type enzyme, the interaction with sphingomyelin is strongly reduced |
731005 |
| 3.1.4.41 | D269G |
site-directed mutagenesis, the mutant shows reduced sphingomyelinase, but unaltered hemolytic activity compared to the wild type enzyme |
731005 |
| 3.1.4.41 | H12A |
mice are exposed to recombinant wild-type phospholipase-D, or to an isoform with a H12A mutation in the catalytic domain resulting in no phospholipasic activity. Renal biopsies from mice treated with the wild-type toxin show glomerular edema, erythrocytes and collapse of Bowmans space, edema and deposition of proteinaceous material within the tubular lumen. An absence of nephrotoxicity is shown in mice treated with the mutated toxin. Analyses of urine and blood show that wild type toxin induces hematuria and elevation of blood urea, while treatment with mutated toxin causes no changes. Mouse lethality experiments also show oliguria and mortality after treatment with wild-type toxin, but not following exposure to the mutated toxin. Wild-type toxin treatment causes cytoplasmic vacuolization, impaired spreading, reduction of cellular viability, and cell-cell and cell-substratum detachment in MDCK cells, while treatment with mutated isoform has no effect |
691130 |
| 3.1.4.41 | H12A |
site-directed mutagenesis |
713659 |
| 3.1.4.41 | H47N |
inactive mutant |
730746 |
| 3.1.4.41 | H49A |
about 65% of wild-type activity |
-, 752302 |
| 3.1.4.41 | H49A |
the mutant shows reduced activity compared to the wild type enzyme |
-, 752303 |
| 3.1.4.41 | N68A |
about 50% of wild-type activity |
-, 752302 |
| 3.1.4.41 | N68A |
the mutant shows reduced activity compared to the wild type enzyme |
-, 752303 |
| 3.1.4.41 | P43A |
about 60% of wild-type activity |
-, 752302 |
